ABSTRACT
Objective To explore the expression of lymphoid-associated antigens in acute myloid leukemia and its clinical significance.Methods 84 patients with de nove (untreated) AML were classified by FAB classification and immunophenotype,of which 53 cases were analyzed by karyotype according to WHO standards.Patients were divided into 2 groups according to whether lymphoid antigen (Ly) was expressed or not.After all patients were treated with a standard remission-induction regimen for 1 course,bone marrow in 63 cases were re examined.Results 49 cases (58.3％) were classified into lymphoid surface antigen-positive acute myeloid leukemia (Ly+ AML) group,35 cases (42.7％) into lymphoid surface antigen-negative acute myeloid leukemia (Ly-AML) group.The incidences of hepatosplenomegaly and lymphadenopathy had significant differences between Ly+AML and Ly AML groups [55.1％ (27 cases) vs.22.9％ (8 cases),t=3.412,P=0.003].There were no significant differences in other indicators between the two groups.On the basis of equal intensity of chemotherapy,complete remission (CR) had no significant difference(x2 =1.995,P=0.158),the disease-free survival (DFS) in Ly + AML group was shorter than in Ly-AML group(t=2.427,P=0.019),the recurrence rate was higher in Ly + AML group than in Ly-AML group(x2 =4.132,P=0.044).Conclusions The expression of lymphoid associated antigens in acute myeloid leukemia is complex.Patients with Ly+AML show poor response to chemotherapy,and have poor prognosis.We should explore new chemotherapy for acute myeloid leukemia.
ABSTRACT
Assessment of minimal residual disease (MRD) in acute myeloid leukemia (AML) patients is now possible by using updated methods including real-time quantitative PCR (RQ-PCR) for abnormal fusion transcripts and multiparameter flow cytometry (MFC) for detecting leukemia-associated phenotypes.Using these techniques,MRD analysis has shown value in terms of risk assessment,continued patient monitoring,and therapeutic decision-making.
ABSTRACT
Objective To investigate the curative effect of the Idarubicin(IDA) in combination with Am-Cand VP16 (IAE) regimen for treatment on refractory acute myelecytic leukemia. Methods Idarubiein 7 mg/m2 iv gtt for 3 days, Ara-C 100 mg/m2 and VP16 100 mg/d iv gtt for 5 days continuously were used as one course.Results Among 17 refractory leukemia patients complete remission was achieved in 9 patients and partial remission in 4 patients, but no remission in 3 patients and one patient died of cerebral hemorrhage after one-two courses of the treatment. Conclusion The IAE regimen for treatment of refractory acute myelocytic leukemia is an effective therapy. The major toxic side effects encountered were marrow suppression,neutropenia and thrombocytopenia. The toxic side effects in heart, liver and kidney were not found.